Certolizumab Pegol

CHEMBL1201831 Phase 4 Approuvé Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A PEGylated antigen-binding fragment (Fab) targeting tumor necrosis factor-alpha (TNF-α), used to reduce inflammation in rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Unlike other anti-TNF biologics, it lacks an Fc region and does not cross the placenta in significant amounts, which has implications for use during pregnancy. PEGylation extends its half-life, allowing subcutaneous dosing every two to four weeks.

Aires thérapeutiques

Melanoma Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Generalized Anxiety Disorder Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Hypertension Atopic Dermatitis Chronic Pain Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A PEGylated antigen-binding fragment (Fab) targeting tumor necrosis factor-alpha (TNF-α), used to reduce inflammation in rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Unlike other anti-TNF biologics, it lacks an Fc region and does not cross the placenta in significant amounts, which has implications for use during pregnancy. PEGylation extends its half-life, allowing subcutaneous dosing every two to four weeks.

Yes, Certolizumab Pegol is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201831. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Certolizumab Pegol sur PillFYI

Données Clés

Synonymes: 1

Liens externes

ChEMBL CHEMBL1201831

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.